The drug, sugammadex sodium, reverses the effects of anesthesia and helps patients regain consciousness after surgery. It was initially submitted for FDA approval in 2008 but rejected due to concerns about allergic reactions and excessive bleeding, according to the release.
Whitehouse Station, N.J.-based Merck submitted new data in January for the FDA to review. If approved, the injection would be the first in a new class of anesthesia drugs.
More Articles on Anesthesia:
Study: Anesthesia May Agitate Patients With Xeroderma Disorder
3-Step Preoperative System Promotes Positive Outcomes
The Disparity Factor: How to Improve Anesthesia Managed Care Contracts
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
